AN2 Therapeutics, Inc. (ANTX)

NASDAQ: ANTX · Real-Time Price · USD

5.93

-0.15 (-2.47%)

At close: Aug 7, 2026, 4:00 PM EDT

5.90

-0.03 (-0.51%)

Pre-market: Aug 10, 2026, 9:00 AM EDT

AN2 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-34.55	-35.17	-51.32	-64.73	-40.96	-21.54
Stock-Based Compensation	5.66	6.25	8.34	8.41	4.39	0.97
Other Adjustments	-0.71	-1.07	-3.28	-2.8	-0.62	0.05
Changes in Accounts Payable	-0.46	-0.3	0.64	0.55	2.5	0.42
Changes in Accrued Expenses	-2.19	-1.66	-4.57	5.69	2.98	1
Changes in Other Operating Activities	0.8	2.12	0.93	-0.41	-1.76	-1.39
Operating Cash Flow	-31.28	-29.83	-49.26	-53.29	-33.46	-20.48
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Purchases of Investments	-26.59	-46.19	-46.75	-132.18	-93.84	-77.27
Proceeds from Sale of Investments	53.99	74.5	101.34	88.9	72.07	27.25
Investing Cash Flow	27.41	28.31	54.59	-43.28	-21.77	-50.02

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Issuance of Common Stock	37.38	0.11	0.37	84.99	70.37	0.01
Repurchase of Common Stock	-	-	-	-	-0.01	-
Net Common Stock Issued (Repurchased)	37.38	0.11	0.37	84.99	70.36	0.01
Issuance of Preferred Stock	-	-	-	-	-	79.73
Net Preferred Stock Issued (Repurchased)	-	-	-	-	-	79.73
Other Financing Activities	-	-	-	-	-	-1.21
Financing Cash Flow	37.38	0.11	0.37	84.99	70.36	78.54

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Cash Flow	33.5	-1.41	5.7	-11.57	15.12	8.03

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-31.28	-29.83	-49.26	-53.29	-33.46	-20.48
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-1.00	-0.99	-1.65	-2.26	-2.18	-7.76
Levered Free Cash Flow	-36.4	-35.01	-54.32	-58.9	-39.06	-28.03
Unlevered Free Cash Flow	-38.97	-37.95	-59.78	-63.8	-38.54	-21.54

SEC Filings: 10-K · 10-Q